Age-associated disparity in phagocytic clearance affects the efficacy of cancer nanotherapeutics

Nanomedicines have been approved to treat multiple human diseases. However, clinical adoption of nanoformulated agents is often hindered by concerns about hepatic uptake and clearance, a process that is not fully understood. Here we show that the antitumour efficacy of cancer nanomedicine exhibits an age-associated disparity. Tumour delivery and treatment outcomes are superior in old versus young mice, probably due to an age-related decline in the ability of hepatic phagocytes to take up and remove nanoparticles. Transcriptomic- and protein-level analysis at the single-cell and bulk levels reveals an age-associated decrease in the numbers of hepatic macrophages that express the scavenger receptor MARCO in mice, non-human primates and humans. Therapeutic blockade of MARCO is shown to decrease the phagocytic uptake of nanoparticles and improve the antitumour effect of clinically approved cancer nanotherapeutics in young but not aged mice. Together, these results reveal an age-associated disparity in the phagocytic clearance of nanotherapeutics that affects their antitumour response, thus providing a strong rationale for an age-appropriate approach to cancer nanomedicine. Here, the authors find a decrease in hepatic phagocytic uptake of nanoparticles in old mice due to age-associated downregulation of the scavenger receptor MARCO, which led to improved tumour delivery and antitumour efficacy of cancer nanomedicine, showing the need to consider age as a factor in therapeutics.

Automated summary

This study reveals an age-associated disparity in the clearance of nanotherapeutics in the liver, showing that old mice have better tumor delivery and antitumor efficacy of cancer nanomedicine due to age-related downregulation of the scavenger receptor MARCO. This highlights the importance of considering age as a factor in cancer nanomedicine therapeutics.